ロード中...
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...
保存先:
| 出版年: | Emerg Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Centers for Disease Control and Prevention
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7392460/ https://ncbi.nlm.nih.gov/pubmed/32687026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3201/eid2608.191499 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|